New treatment options for castrate-resistant prostate cancer: A urology perspective

Canadian Journal of Urology

Volumn 18, Issue 4, 2011, Pages 5767-5777

  Gomella, Leonard G ^a   Gelpi, Francisco ^a   Kelly, William Kevin ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Castrationresistant prostate cancer; Metastatic; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CABAZITAXEL; DOCETAXEL; SIPULEUCEL T; TAXOID; TISSUE EXTRACT;

ADJUVANT CHEMOTHERAPY; HUMAN; MALE; ORCHIECTOMY; PROSTATE TUMOR; REVIEW;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS; TISSUE EXTRACTS;

EID: 84855983681     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Siegel R Ward E, Brawley O, Jemal A. Cancer Statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-236.
2. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007;82(2):243-249.
3. Gomella LG, Lin J, Hoffman-Censits J et al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 2010;6(6):e5-e10.
4. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-1159.
5. Hanks GE, Hanlon AL, Schultheiss TE et al. Conformal external beam treatment of prostate cancer. Urology 1997;50(1):87-92.
6. Chi KN, Bjartell A, Dearnaley D et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009;56(4):594-605.
7. Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67(10):5033-5041.
8. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15):6407-6415.
9. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005.
10. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
11. Taxotere (docetaxel) [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2004.
12. Jevtana (cabazitaxel) [package insert]. Bridgewater, NJ: sanofi- aventis U.S. LLC; 2010.
13. Kibel AS. An interdisciplinary approach to treating prostate cancer. Urology 2005;65(6)(suppl):13-18.
14. National Comprehensive Cancer Network. Prostate cancer. v.1.2011. http://www.nccn.org/professionals/physician_gls/ pdf/prostate.pdf. Accessed January 15, 2011.
15. Cancer and Leukemia Group B; National Cancer Institute. Surgery with or without docetaxel and leuprolide or goserelin in treating patients with high-risk localized prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00430183 NLM Identifier: NCT00430183.
16. Sanofi-Aventis. A study of androgen deprivation with leuprolide, +/-docetaxel for clinically asymptomatic prostate cancer subjects with a rising PSA. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00514917 NLM Identifier: NCT00514917.
17. Department of Veteran Affairs; Sanofi-Aventis. Chemotherapy after prostatectomy (CAP) for high risk prostate carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00132301 NLM Identifier: NCT00132301.
18. Radiation Therapy Oncology Group. RTOG 0521. A phase III protocol of androgen suppression (AS) and 3DCTR/IMRT vs. AS and 3DCRT/IMRT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer. Available from URL: http://208.251.169.72/members/protocols/0521/0521.pdf Accessed January 15, 2011.
19. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-1764.
20. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506-2513.
21. Novantrone (mitoxantrone) [package insert]. Rockland, MA: EMD Serono, Inc.; 2010.
22. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
23. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520.
24. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-245.
25. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-1154.
26. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
27. Provenge (sipuleucel-T) [package insert]. Seattle, WA: Dendreon Corporation; 2010.
28. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-3094.
29. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-3679.
30. Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol 2010;6(5):665-679.
31. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28(9):1489-1495.
32. Cougar Biotechnology, Inc. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castrationresistant prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00887198 NLM Identifier: NCT00887198.
33. Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer [published online ahead of print May 17, 2011]. Prostate Cancer Prostatic Dis doi:10.1038/pcan.2011.23.
34. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-1446.
35. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-790.
36. Medivation, Inc; Astellas Pharma, Inc. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01212991 NLM Identifier: NCT01212991.
37. Medivation, Inc. Safety and efficacy study of MDV3100 in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy (AFFIRM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00974311 NLM Identifier: NCT00974311.
38. Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011;185(3):787-794.
39. James ND, Caty A, Payne H et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010;106(7):966-973.
40. AstraZeneca. A phase III trial of ZD4054 (zibotentan) (endothelin A antagonist) in hormone resistant prostate cancer with bone metastases (ENTHUSE M1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2011 Jan 15]. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00554229 NLM Identifier: NCT00554229.
41. AstraZeneca. A phase III trial of ZD4054 (zibotentan) (endothelin A antagonist) and docetaxel in metastatic hormone resistant prostate cancer (ENTHUSE M1C). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00617669 NLM Identifier: NCT00617669.
42. Results of zibotentan phase III trial in castration resistant prostate cancer [press release]. AstraZeneca; September 27, 2010.
43. AstraZeneca. A phase III trial of ZD4054 (zibotentan) (endothelin A antagonist) in non-metastatic hormone resistant prostate cancer (ENTHUSE M0). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00626548 NLM Identifier: NCT00626548.
44. Southwest Oncology Group; National Cancer Institute. Docetaxel and prednisone with or without atrasentan in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00134056 NLM Identifier: NCT00134056.
45. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-5438.
46. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-1815.
47. Bristol-Myers Squibb. Phase 3 study of immunotherapy to treat advanced prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT01057810 NLM Identifier: NCT01057810.
48. Bristol-Myers Squibb. Study of immunotherapy to treat advanced prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2011 Jan 15]. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00861614 NLM Identifier: NCT00861614.
49. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(27):4247-4254.
50. Teva Pharmaceuticals USA; OncoGenEx Technologies. Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01188187 NLM Identifier: NCT01188187.
51. OncoGenEx Technologies; Teva Pharmaceuticals USA. A study evaluating the clinical benefit of adding custirsen to docetaxel retreatment/prednisone as second line therapy in men with castrate resistant prostate cancer (CRPC). In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www. clinicaltrials.gov/ct2/show/NCT01083615 NLM Identifier: NCT01083615.
52. Schutz FA, Oh WK. Neoadjuvant and adjuvant therapies in prostate cancer. Urol Clin North Am 2010;37(1):97-104.
53. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 1997;79(11):2154-2161.
54. Horwitz EM, Vicini FA, Ziaja EL et al. An analysis of clinical and treatment related prognostic factors on outcome using biochemical control as an end-point in patients with prostate cancer treated with external beam irradiation. Radiother Oncol 1997;44(3):223-228.
55. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63(6):1138-1142.
56. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233-5240.
57. Kelly WK, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19(1):44-53.
58. Kelly WK, Halabi S, Elfiky A et al. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer 2008;113(11):3137-3145.
59. Eastham JA, Kelly WK, Grossfeld GD, Small EJ; Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(suppl 1):55-62.
60. Kibel AS, Rosenbaum E, Kattan MW et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;177(5):1777-1781.
61. Cetnar JP, Malkowicz SB, Palmer SC, Wein AJ, Vaughn DJ. Pilot trial of adjuvant paclitaxel plus estramustine in resected highrisk prostate cancer. Urology 2008;71(5):942-946.
62. Ploussard G, Paule B, Salomon L et al. Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer Prostatic Dis 2010;13(1):97-101.
63. Flaig TW, Tangen CM, Hussain MH et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26(9):1532-1536.
64. Rosenthal SA, Bae K, Pienta KJ et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys 2009;73(3):672-678.
65. Radiation Therapy Oncology Group; National Cancer Institute. Hormone therapy and radiation therapy or hormone therapy and radiation therapy followed by docetaxel and prednisone in treating patients with localized prostate cancer. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00288080 NLM Identifier: NCT00288080.
66. Hussain A, Wu Y, Mirmiran A et al. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy [published online ahead of print October 30, 2010]. Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.09.009.
67. Dibiase SJ, Hussain A, Kataria R et al. Long-term results of a prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer [published online ahead of print October 30, 2010]. Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.06.042.
68. University of Texas; National Cancer Institute. Docetaxel, radiation therapy, and prednisone in treating patients who have undergone surgery for prostate cancer. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00348816 NLM Identifier: NCT00348816.
69. Millennium Pharmaceuticals, Inc. Study comparing orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://clinicaltrials. gov/ct2/show/NCT01193244 NLM Identifier: NCT01193244.
70. Millennium Pharmaceuticals, Inc. Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 15]. Available from: http://clinicaltrials.gov/ct2/show/ NCT01193257 NLM Identifier: NCT01193257.